



PATENT

#14
JPL
7/30/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: IGOR YUHPYNG L. CHEN

FOR: CORTICOTROPIN RELEASING FACTOR ANTAGONISTS

Attorney Docket No.: U 014293-3

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants wish to bring to the Examiner's attention the following co-pending

U.S. Patents applications:

09/761,995 (copy attached)

09/580,287 (Dwayne C. Jones)

09/580,281 (Dwayne C. Jones)

09/583,256 (Dwayne C. Jones)

09/583,372 (Dwayne C. Jones)

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is **mandatory**;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.
37 C.F.R. 1.8(a)

☐ with sufficient postage as first class mail.

37 C.F.R. 1.10*

☒ as "Express Mail Post Office to Addressee"
Mailing Label EV 327548955 US
(mandatory)

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Cynthia Padgett

Date: JULY 17, 2003

CYNTHIA PADGETT

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

EXPRESS MAIL LABEL
NO.: EV 327548955 US

INFORMATION DISCLOSURE CITATION

(several sheets if necessary)

ATTY. DOCKET NO. PC8605B


SERIAL NO. 09/580,791

APPLICANT YUHPYNG L. CHEN

FILING DATE MAY 30, 2000

GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
 US	4		0	5	6	4	2	8/12/86	Rivier, et al.	514	12		
	US	4	8	3	9	3	5	3	6/13/89	Hosoi, et al.	514	212	
	US	5	0	6	3	2	4	5	11/5/91	Abreu, et al.	514	404	
	US	5	6	9	1	3	6	4	11/25/97	Buckman, et al.	514	341	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO
EP 0 4 7 5 4 1 1	3/18/92	EPO			
EP 0 4 8 2 8 0 4		EPO			
DE 3 1 4 5 2 8 7	5/19/83	Germany	487	04	
WO 9 4 1 3 6 7 6	6/23/94	PCT	487	04	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	Chalmers, D.T., et al., "Corticotrophin-releasing factors molecular biology to drug design". Trends in Pharmacological Sciences, (1996), Vol. 17, pgs 166-172
✓	Cossey, A. L., et al. "Pyridines & Pyridinium Salts from Cyanoacetamides" Australian Journal of Chem. (1976), 29, pg1039-50
✓	Owens, et al., "Physiology and Pharmacology of Corticotropin-releasing factor", Pharm. Rev., (1991), Vol 43, pgs 425-473
✓	Fujikawa, K., et al. "Herbicidal activities of phenoxy pyridines". Chemical Abstract, (1970), Abstract No. 11080v
✓	Fujikawa, K., et al. "Studies on Herbicidal Activities of Phenoxy pyridines". Agr. Biol. Chemical, (1970), Vol. 34, No.1 pg 68-79
✓	DeSouza, E.B., "Corticotropin-releasing Factor Receptors Physiology, Pharmacology, Biochemistry & Role in Central Nervous System & Immune Disorders.", (1995), Vol. 20, No. 8, pgs. 789-819.
✓	Fackelmann, K.A. & Raloff, J. "Psychological Street Linked to Cancer", Science News, (Sept. 25, 1993), Vol. 144, pg 196
✓	Lyons, M.K., et al., "Corticotropin releasing factor antagonist reduces ischemic hippocampal neuronal injury", Brain Research, (1991), Vol. 545, Issue 1-2, pgs 339-342
✓	Stratakis, C.A. & Chrousos, G. P., "Hypothalamic Hormones, GnRH, TRH, CHRH, SRIF, CRH, & Dopamine, Endocrinology" Basic & Clinical Principles, (1997), pgs 185-209 (Humana Press, Tofowa, NJ, 1997)
✓	Strijbos, P. J. L. M., et al. Brain Research, Vol. 656, (1991), pgs 405-408
✓	Robins, M.J., et al., Can. J. Chem. (1977), Vol. 55, pgs 1252-59

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.